-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

844 An ‘Off-the-Shelf,’ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

Adoptive Immunotherapy
Program: Oral and Poster Abstracts
Type: Oral
Session: 703. Adoptive Immunotherapy: Gene Engineered T cells for Hematologic Malignancies
Monday, December 11, 2017: 5:15 PM
Bldg B, Lvl 2, B206 (Georgia World Congress Center)

Matt L Cooper, PhD1, Jaebok Choi, PhD2, Karl W. Staser3*, Julie Ritchey2*, Jessica Niswonger2*, Kayla Eckardt2*, Michael P Rettig, PhD4, Wang Bing2*, Linda G Eissenberg, PhD2*, Armin Ghobadi, MD2*, Leah Gehrs2*, Julie Prior, PhD5*, Samuel Achilefu5*, Christopher A Miller, PhD6*, Catrina Fronick6*, Julie O'Neal, PhD2*, Feng Gao, PhD7*, David M. Weinstock, MD8, Alejandro Gutierrez, MD9, Robert S Fulton6* and John F DiPersio, MD, PhD2

1Department of Medicine, Division of Oncology, Washington University, Saint Louis, MO
2Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
3Division of Dermatology, Washington University School of Medicine, St Louis
4Department of Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
5Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO
6McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO
7Dvision of Biostatistics, Washington University School of Medicine, St. Louis, MO
8Dana-Farber Cancer Institute, Boston, MA
9Department of Pediatric Oncology, Children's Hospital Boston, Boston, MA

T cell malignancies represent a class of devastating hematologic cancers with high rates of relapse and mortality in both children and adults for which there are currently no effective or targeted therapies. Despite intensive multi-agent chemotherapy regimens, fewer than 50% of adults and 75% of children with T-ALL survive beyond five years. For those who relapse after initial therapy, salvage chemotherapy regimens induce remissions in 20-40% of cases. Allogeneic stem cell transplant, with its associated risks and toxicities, is the only curative therapy.

T cells engineered to express a chimeric antigen receptor (CAR) are a promising cancer immunotherapy. Such targeted therapies have shown great potential for inducing both remissions and even long-term relapse-free survival in patients with B cell leukemia and lymphoma7-9. Thus, a targeted therapy against T cell malignancies represents a significant unmet medical need. However, several challenges have limited the clinical development of CAR-T cells against T cell malignancies. First, the shared expression of target antigens between T effector cells and T cell malignancies results in fratricide, or self-killing, of CAR-T cells. Second, harvesting adequate numbers of autologous T cells, without contamination by malignant cells is, at best, technically challenging and prohibitively expensive. Third, the use of genetically modified CAR-T cells from allogeneic donors may result in life-threatening graft-vs.-host disease (GvHD) when infused into immune-compromised HLA-matched or mismatched recipients.

We hypothesized that deletion of CD7 and the T cell receptor alpha chain (TRAC) using CRISPR/Cas9 in CAR-T targeting CD7 (UCART7) would result in the efficient targeting and killing of malignant T cells without significant effector T cell fratricide or induction of GvHD.

To generate the CD7 CAR, the anti-CD7 single chain variable fragment (scFv) was created using commercial gene synthesis and cloned into the backbone of a 3rd generation CAR with CD28 and 4-1BB internal signaling domains. The construct was modified to express CD34 via a P2A peptide to enable detection of CAR following viral transduction. Human primary T cells were activated using anti-CD3/CD28 beads for 48 hours prior to bead removal and electroporation with CD7 gRNA, TRAC gRNA, and Cas9 mRNA. On day three, T cells were transduced with lentivirus particles encoding either CD7 CAR or CAR CD19 control and allowed to expand for a further 6 days. Transduction efficiency and ablation of CD7 and TRAC were confirmed by flow cytometry. Multiplex CRISPR/Cas9 gene-editing resulted in the simultaneous bi-allelic deletion of both CD7 and TRAC in 72.8%±1.92 of cells, as determined by both non-homologous end joining (NHEJ) and FACS analyses. To prevent alloreactivity, CD3+ CAR-T were removed from the product by magnetic depletion. Of particular importance is that by using two distinct methods for assessing “off-target” nuclease activity across the entire human T cell genome (Guide-seq and probe capture), we could only detect one gene, an intronic modification of RMB33, that was inappropriately targeted using this approach. No obvious genomic rearrangements were detected by these analyses.

UCART7 effectively expanded and killed T-ALL cell lines (CCRF-CEM, MOLT3, and HSB2) and human primary T-ALL blasts in vitro. Next, we tested the capacity of UCART7 to kill primary T-ALL in vivo without xenogeneic GvHD. Considerable expansion of alloreactive T cells, severe GvHD (mean clinical GvHD score = 5.66), and a robust graft vs. leukemia effect were observed in recipients of WT T cells. In contrast, GvHD was completely absent, T cells were undetectable, and considerable tumor burden was observed in mice receiving TRACΔ T cells. Mice receiving UCART7, however, had no GvHD and, unlike UCART19 controls, effectively cleared primary human T-ALL in NSG mice.

Fratricide-resistant and allo-tolerant ‘off-the-shelf’ UCART7 signifies a novel strategy for treatment of relapsed and refractory T-ALL and non-Hodgkin’s T cell lymphomas without a requirement for autologous T cells and represents the first clinically feasible adoptive T cell therapy for T cell malignancies.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH